{"organizations": [], "uuid": "181e925d6755883c2cf98baa774dc84d0dc46656", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/05/10/cramer-vets-biotech-giants-biogen-celgene-gilead-and-regeneron.html?__source=yahoo%7Cfinance%7Cheadline%7Cstory%7C&amp;par=yahoo&amp;yptr=yahoo", "country": "US", "domain_rank": 767, "title": "Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.03, "site_type": "news", "published": "2018-05-10T03:00:00.000+03:00", "replies_count": 0, "uuid": "181e925d6755883c2cf98baa774dc84d0dc46656"}, "author": "Elizabeth Gurdus", "url": "https://www.cnbc.com/2018/05/10/cramer-vets-biotech-giants-biogen-celgene-gilead-and-regeneron.html?__source=yahoo%7Cfinance%7Cheadline%7Cstory%7C&amp;par=yahoo&amp;yptr=yahoo", "ord_in_thread": 0, "title": "Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects", "locations": [], "entities": {"persons": [{"name": "elizabeth gu", "sentiment": "negative"}, {"name": "cramer", "sentiment": "negative"}, {"name": "jim cramer", "sentiment": "none"}], "locations": [], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "celgene", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "cnbc", "sentiment": "none"}, {"name": "celgene celg", "sentiment": "none"}, {"name": "biogen biib", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects Elizabeth Gurdus Reblog \"Mad Money\" host Jim Cramer examines \"the four horsemen of biotech\" to see if their weakening stocks can regain momentum. With a major market comeback underway, CNBC's Jim Cramer zeroed in on four key stocks in a sector that's not getting much love: biotechnology. Biogen BIIB , Celgene CELG , Regeneron REGN and Gilead GILD — some of the sector's most prominent names that Cramer labeled \"the four horsemen of biotech\" — have become outright hated by investors. ", "external_links": [], "published": "2018-05-10T03:00:00.000+03:00", "crawled": "2018-05-11T04:24:38.003+03:00", "highlightTitle": ""}